nach oben

Erschienen in:

05.05.2018 | Original Article

¹⁸F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT_1A receptor agonist for PET neuroimaging

verfasst von: Benjamin Vidal, Sylvain Fieux, Matthieu Colom, Thierry Billard, Caroline Bouillot, Olivier Barret, Cristian Constantinescu, Gilles Tamagnan, Adrian Newman-Tancredi, Luc Zimmer

Erschienen in: Brain Structure and Function | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Serotonin 1A receptors are known to play an important role in many psychiatric and neurodegenerative disorders. Currently, all available 5-HT_1A receptor PET radiopharmaceuticals that are radiolabeled with fluorine-18 are antagonists. As agonists bind preferentially to the high-affinity state of receptors, it would be of great interest to develop agonist radioligands which could provide a measure of the functional 5-HT_1A receptors in pathophysiological processes. The 5-HT_1A receptor agonist candidates we recently proposed had promising in vitro properties but were not optimal in terms of PET imaging. F13640, a.k.a befiradol or NLX-112, is a 5-HT_1A receptor agonist with a high affinity (Ki = 1 nM) and a high selectivity that would be suitable for a potential PET radiopharmaceutical. With propose here the first preclinical evaluation of ¹⁸F-F13640. ¹⁸F-F13640’s nitro-precursor was synthesized and radiolabeled via a fluoro-nucleophilic substitution. Its radiopharmacological characterization included autoradiographic studies, metabolic studies, and in vivo PET scans in rat, cat and non-human primate. Some of the results were compared with the radiotracer ¹⁸F-MPPF, a 5-HT_1A receptor antagonist. The radiochemical purity of ¹⁸F-F13640 was > 98%. In vitro binding pattern was consistent with the 5-HT_1A receptor distribution. Metabolic studies revealed that the radiotracer rapidly entered the brain and led to few brain radiometabolites. Although ¹⁸F-F13640 in vivo binding was blocked by the 5-HT_1A antagonist WAY-100635 and the 5-HT_1A agonist 8-OH-DPAT, the distribution pattern was markedly different from antagonist radiotracers in the three species, suggesting it provides novel information on 5-HT_1A receptors. Preliminary studies also suggest a high sensitivity of ¹⁸F-F13640 to endogenous serotonin release. ¹⁸F-F13640 has suitable characteristics for probing in vitro and in vivo the 5-HT_1A receptors in high-affinity state. Quantification analyses with kinetic modeling are in progress to prepare the first-in-man study of ¹⁸F-F13640.

Andrade R, Huereca D, Lyons JG, Andrade EM, McGregor KM (2015) 5-HT1A receptor-mediated autoinhibition and the control of serotonergic cell firing. ACS Chem Neurosci 6(7):1110–1115. https://doi.org/10.1021/acschemneuro.5b00034 CrossRefPubMedPubMedCentral

Avissar S, Schreiber G (2006) The involvement of G proteins and regulators of receptor-G protein coupling in the pathophysiology, diagnosis and treatment of mood disorders. Clin Chim Acta (1–2):37–47. https://doi.org/10.1016/j.cca.2005.11.003

Aznavour N, Rbah L, Leger L, Buda C, Sastre JP, Imhof A, Charnay Y, Zimmer L (2006) A comparison of in vivo and in vitro neuroimaging of 5-HT 1A receptor binding sites in the cat brain. J Chem Neuroanat 31(3):226–232. https://doi.org/10.1016/j.jchemneu.2006.01.006 CrossRefPubMed

Bantick RA, Montgomery AJ, Bench CJ, Choudhry T, Malek N, McKenna PJ, Quested DJ, Deakin JF, Grasby PM (2004a) A positron emission tomography study of the 5-HT1A receptor in schizophrenia and during clozapine treatment. J Psychopharmacol (3):346–354. https://doi.org/10.1177/026988110401800304

Bantick RA, Rabiner EA, Hirani E, de Vries MH, Hume SP, Grasby PM (2004b) Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology 29(5):847–859. https://doi.org/10.1038/sj.npp.1300390 CrossRefPubMed

Becker G, Streichenberger N, Billard T, Newman-Tancredi A, Zimmer L (2014) A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer’s disease. CNS Neurosci Ther 20(10):930–934. https://doi.org/10.1111/cns.12306 CrossRefPubMed

Bishop C, Krolewski DM, Eskow KL, Barnum CJ, Dupre KB, Deak T, Walker PD (2009) Contribution of the striatum to the effects of 5-HT1A receptor stimulation in L-DOPA-treated hemiparkinsonian rats. J Neurosci Res 87(7):1645–1658. https://doi.org/10.1002/jnr.21978 CrossRefPubMedPubMedCentral

Colpaert FC, Tarayre JP, Koek W, Pauwels PJ, Bardin L, Xu XJ, Wiesenfeld-Hallin Z, Cosi C, Carilla-Durand E, Assie MB, Vacher B (2002) Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. Neuropharmacology 43(6):945–958CrossRefPubMed

Ganz M, Feng L, Hansen HD, Beliveau V, Svarer C, Knudsen GM, Greve DN (2017) Cerebellar heterogeneity and its impact on PET data quantification of 5-HT receptor radioligands. J Cereb Blood Flow Metab 37(9):3243–3252. https://doi.org/10.1177/0271678X16686092 CrossRefPubMedPubMedCentral

Gozlan H, Thibault S, Laporte AM, Lima L, Hamon M (1995) The selective 5-HT1A antagonist radioligand [3H]WAY 100635 labels both G-protein-coupled and free 5-HT1A receptors in rat brain membranes. Eur J Pharmacol 288(2):173–186CrossRefPubMed

Hendry N, Christie I, Rabiner EA, Laruelle M, Watson J (2011) In vitro assessment of the agonist properties of the novel 5-HT1A receptor ligand, CUMI-101 (MMP), in rat brain tissue. Nucl Med Biol 38(2):273–277. https://doi.org/10.1016/j.nucmedbio.2010.08.003 CrossRefPubMed

Heusler P, Palmier C, Tardif S, Bernois S, Colpaert FC, Cussac D (2010) [(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand. Naunyn Schmiedebergs Arch Pharmacol 382(4):321–330. https://doi.org/10.1007/s00210-010-0551-4 CrossRefPubMed

Hirvonen J, Kajander J, Allonen T, Oikonen V, Nagren K, Hietala J (2007) Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region. J Cereb Blood Flow Metab 27(1):185–195. https://doi.org/10.1038/sj.jcbfm.9600326 CrossRefPubMed

Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortere R, Cenci MA, Newman-Tancredi A (2015) NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Exp Neurol 271:335–350. https://doi.org/10.1016/j.expneurol.2015.05.021 CrossRefPubMed

Jagoda EM, Lang L, Tokugawa J, Simmons A, Ma Y, Contoreggi C, Kiesewetter D, Eckelman WC (2006) Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT. Synapse 59(6):330–341. https://doi.org/10.1002/syn.20246 CrossRefPubMed

Kumar JS, Prabhakaran J, Majo VJ, Milak MS, Hsiung SC, Tamir H, Simpson NR, Van Heertum RL, Mann JJ, Parsey RV (2007) Synthesis and in vivo evaluation of a novel 5-HT1A receptor agonist radioligand [O-methyl- 11C]2-(4-(4-(2-methoxyphenyl)piperazin-1-yl)butyl)-4-methyl-1,2,4-triazine-3,5(2H,4H)dione in nonhuman primates. Eur J Nucl Med Mol Imaging 34(7):1050–1060. https://doi.org/10.1007/s00259-006-0324-y CrossRefPubMed

Kumar JS, Parsey RV, Kassir SA, Majo VJ, Milak MS, Prabhakaran J, Simpson NR, Underwood MD, Mann JJ, Arango V (2013) Autoradiographic evaluation of [3H]CUMI-101, a novel, selective 5-HT1AR ligand in human and baboon brain. Brain Res 1507:11–18. https://doi.org/10.1016/j.brainres.2013.02.035 CrossRefPubMed

Lancelot S, Roche R, Slimen A, Bouillot C, Levigoureux E, Langlois JB, Zimmer L, Costes N (2014) A multi-atlas based method for automated anatomical rat brain MRI segmentation and extraction of PET activity. PloS one 9(10):e109113. https://doi.org/10.1371/journal.pone.0109113 CrossRefPubMedPubMedCentral

Lanfumey L, Hamon M (2000) Central 5-HT(1A) receptors: regional distribution and functional characteristics. Nucl Med Biol 27(5):429–435CrossRefPubMed

Le Bars D, Lemaire C, Ginovart N, Plenevaux A, Aerts J, Brihaye C, Hassoun W, Leviel V, Mekhsian P, Weissmann D, Pujol JF, Luxen A, Comar D (1998) High-yield radiosynthesis and preliminary in vivo evaluation of p-[18F]MPPF, a fluoro analog of WAY-100635. Nucl Med Biol 25(4):343–350CrossRefPubMed

Lemoine L, Verdurand M, Vacher B, Blanc E, Le Bars D, Newman-Tancredi A, Zimmer L (2010) [18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur J Nucl Med Mol Imaging 37(3):594–605. https://doi.org/10.1007/s00259-009-1274-y CrossRefPubMed

Lemoine L, Becker G, Vacher B, Billard T, Lancelot S, Newman-Tancredi A, Zimmer L (2012) Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging. J Nucl Med 53(6):969–976. https://doi.org/10.2967/jnumed.111.101212 CrossRefPubMed

Mannoury la Cour C, El Mestikawy S, Hanoun N, Hamon M, Lanfumey L (2006) Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain. Mol Pharmacol 70(3):1013–1021. https://doi.org/10.1124/mol.106.022756 CrossRefPubMed

Maurel JL, Autin JM, Funes P, Newman-Tancredi A, Colpaert F, Vacher B (2007) High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. J Med Chem (20):5024–5033. https://doi.org/10.1021/jm070714l CrossRef

Meadows SM, Chambers NE, Conti MM, Bossert SC, Tasber C, Sheena E, Varney M, Newman-Tancredi A, Bishop C (2017) Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia. Exp Neurol 292:168–178. https://doi.org/10.1016/j.expneurol.2017.03.013 CrossRefPubMed

Milak MS, DeLorenzo C, Zanderigo F, Prabhakaran J, Kumar JS, Majo VJ, Mann JJ, Parsey RV (2010) In vivo quantification of human serotonin 1A receptor using 11C-CUMI-101, an agonist PET radiotracer. J Nucl Med 51(12):1892–1900. https://doi.org/10.2967/jnumed.110.076257 CrossRefPubMed

Mongeau R, Welner SA, Quirion R, Suranyi-Cadotte BE (1992) Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus. Brain Res 590(1–2):229–238CrossRefPubMed

Newman-Tancredi A, Martel JC, Cosi C, Heusler P, Lestienne F, Varney MA, Cussac D (2017) Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist. J Pharm Pharmacol 69(9):1178–1190. https://doi.org/10.1111/jphp.12762 CrossRefPubMed

Parsey RV, Arango V, Olvet DM, Oquendo MA, Van Heertum RL, John Mann J (2005) Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab 25(7):785–793. https://doi.org/10.1038/sj.jcbfm.9600072 CrossRefPubMed

Paterson LM, Tyacke RJ, Nutt DJ, Knudsen GM (2010) Measuring endogenous 5-HT release by emission tomography: promises and pitfalls. J Cereb Blood Flow Metab 30(10):1682–1706. https://doi.org/10.1038/jcbfm.2010.104 CrossRefPubMedPubMedCentral

Pauwels PJ, Colpaert FC (2003) Ca2 + responses in Chinese hamster ovary-K1 cells demonstrate an atypical pattern of ligand-induced 5-HT1A receptor activation. J Pharmacol Exp Ther 307(2):608–614. https://doi.org/10.1124/jpet.103.055871 CrossRefPubMed

Paxinos G, Watson C (1986) The rat brain in stereotaxic coordinates. Academic Press, New York

Pinborg LH, Feng L, Haahr ME, Gillings N, Dyssegaard A, Madsen J, Svarer C, Yndgaard S, Kjaer TW, Parsey RV, Hansen HD, Ettrup A, Paulson OB, Knudsen GM (2012) No change in [(1)(1)C]CUMI-101 binding to 5-HT(1A) receptors after intravenous citalopram in human. Synapse 66(10):880–884. https://doi.org/10.1002/syn.21579 CrossRefPubMed

Pucadyil TJ, Chattopadhyay A (2007) The human serotonin1A receptor exhibits G-protein-dependent cell surface dynamics. Glycoconj J 24(1):25–31. https://doi.org/10.1007/s10719-006-9008-x CrossRefPubMed

Ren J, Ding X, Greer JJ (2015) 5-HT1A receptor agonist Befiradol reduces fentanyl-induced respiratory depression, analgesia, and sedation in rats. Anesthesiology 122(2):424–434. https://doi.org/10.1097/ALN.0000000000000490 CrossRefPubMed

Rohlfing T, Kroenke CD, Sullivan EV, Dubach MF, Bowden DM, Grant KA, Pfefferbaum A (2012) The INIA19 Template and NeuroMaps Atlas for Primate Brain Image Parcellation and Spatial Normalization. Front Neuroinf 6:27. https://doi.org/10.3389/fninf.2012.00027 CrossRef

Shrestha SS, Liow JS, Lu S, Jenko K, Gladding RL, Svenningsson P, Morse CL, Zoghbi SS, Pike VW, Innis RB (2014) (11)C-CUMI-101, a PET radioligand, behaves as a serotonin 1A receptor antagonist and also binds to alpha(1) adrenoceptors in brain. J Nucl Med 55(1):141–146. https://doi.org/10.2967/jnumed.113.125831 CrossRefPubMedPubMedCentral

Shrestha SS, Liow JS, Jenko K, Ikawa M, Zoghbi SS, Innis RB (2016) The 5-HT1A Receptor PET Radioligand 11C-CUMI-101 Has Significant Binding to alpha1-Adrenoceptors in Human Cerebellum, Limiting Its Use as a Reference Region. J Nucl Med 57(12):1945–1948. https://doi.org/10.2967/jnumed.116.174151 CrossRefPubMedPubMedCentral

Tavares A, Becker G, Barret O, Morley T, Alagille D, Vacher B, Newman-Tancredi A, Tamagnan G, Zimmer L (2013) Initial evaluation of [18F]F13714, a novel 5-HT1A receptor agonist in non-human primates. Annual Congress of EANM

Udo de Haes JI, Harada N, Elsinga PH, Maguire RP, Tsukada H (2006) Effect of fenfluramine-induced increases in serotonin release on [18F]MPPF binding: a continuous infusion PET study in conscious monkeys. Synapse 59(1):18–26. https://doi.org/10.1002/syn.20209 CrossRefPubMed

Vidal B, Sebti J, Verdurand M, Fieux S, Billard T, Streichenberger N, Troakes C, Newman-Tancredi A, Zimmer L (2016) Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer’s disease: a post-mortem study with PET radiopharmaceuticals. Neuropharmacology 109:88–95. https://doi.org/10.1016/j.neuropharm.2016.05.009 CrossRefPubMed

Wurch T, Colpaert FC, Pauwels PJ (2003) Mutation in a protein kinase C phosphorylation site of the 5-HT1A receptor preferentially attenuates Ca2 + responses to partial as opposed to higher-efficacy 5-HT1A agonists. Neuropharmacology 44(7):873–881CrossRefPubMed

Yokoyama C, Mawatari A, Kawasaki A, Takeda C, Onoe K, Doi H, Newman-Tancredi A, Zimmer L, Onoe H (2016) Marmoset serotonin 5-HT1A receptor mapping with a biased agonist PET probe 18F-F13714: comparison with an antagonist tracer 18F-MPPF in awake and anesthetized states. Int J Neuropsychopharmacol 19 (12). https://doi.org/10.1093/ijnp/pyw079

Zimmer L (2016) Pharmacological agonists for more-targeted CNS radio-pharmaceuticals. Oncotarget 7(49):80111–80112. https://doi.org/10.18632/oncotarget.13418 CrossRefPubMedPubMedCentral

Zimmer L, Le Bars D (2013) Current status of positron emission tomography radiotracers for serotonin receptors in humans. J Labelled Comp Radiopharm 56(3–4):105–113. https://doi.org/10.1002/jlcr.3001 CrossRefPubMed

Titel: 18F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging
verfasst von: Benjamin Vidal
Sylvain Fieux
Matthieu Colom
Thierry Billard
Caroline Bouillot
Olivier Barret
Cristian Constantinescu
Gilles Tamagnan
Adrian Newman-Tancredi
Luc Zimmer
Publikationsdatum: 05.05.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Brain Structure and Function / Ausgabe 6/2018
Print ISSN: 1863-2653
Elektronische ISSN: 1863-2661
DOI: https://doi.org/10.1007/s00429-018-1672-7

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

Psychotherapie Medizin aktuell

Fünf Jahren nach der Neugestaltung der Psychotherapie-Richtlinie wurden jetzt die Effekte der vorgenommenen Änderungen ausgewertet. Das Hauptziel der Novellierung war eine kürzere Wartezeit auf Therapieplätze. Dieses Ziel wurde nicht erreicht, es gab jedoch positive Auswirkungen auf andere Bereiche.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

¹⁸F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT_1A receptor agonist for PET neuroimaging

Abstract

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Is visual activation associated with changes in cerebral high-energy phosphate levels?

Pattern separation in the hippocampus: distinct circuits under different conditions

Molecular composition of the human primary visual cortex profiled by multimodal mass spectrometry imaging

The neural correlates of arithmetic difficulty depend on mathematical ability: evidence from combined fNIRS and ERP

Frontal cortical control of posterior sensory and association cortices through the claustrum

In vivo relationship between serotonin 1A receptor binding and gray matter volume in the healthy brain and in major depressive disorder

Leitlinien kompakt für die Neurologie

Neu im Fachgebiet Neurologie

Wartezeit nicht kürzer, aber Arbeit flexibler

„Restriktion auf vier Wochen Therapie bei Schlaflosigkeit ist absurd!“

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

Update Neurologie